Literature DB >> 26405610

New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer.

Louisa S Chard1, Nicholas R Lemoine2, Yaohe Wang2.   

Abstract

Although the profile of safety of tumor-targeted oncolytic virus (TOV) is encouraging, the antitumor efficacy of TOV alone is disappointing. Interleukin-10 (IL-10) plays an important role in carcinogenesis and anti-virus immunity. Here we report that tumor-targeted oncolytic vaccinia virus (VV) armed with IL10 shows promising potential for treatment of pancreatic cancer (PaCa).

Entities:  

Keywords:  IL-10; immunotherapy; oncolytic virus; pancreatic cancer; vaccinia virus

Year:  2015        PMID： 26405610      PMCID： PMC4570121          DOI： 10.1080/2162402X.2015.1038689

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  IL-10: the master regulator of immunity to infection.

Authors:  Kevin N Couper; Daniel G Blount; Eleanor M Riley
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

2.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Authors:  Caroline J Breitbach; James Burke; Derek Jonker; Joe Stephenson; Andrew R Haas; Laura Q M Chow; Jorge Nieva; Tae-Ho Hwang; Anne Moon; Richard Patt; Adina Pelusio; Fabrice Le Boeuf; Joe Burns; Laura Evgin; Naomi De Silva; Sara Cvancic; Terri Robertson; Ji-Eun Je; Yeon-Sook Lee; Kelley Parato; Jean-Simon Diallo; Aaron Fenster; Manijeh Daneshmand; John C Bell; David H Kirn
Journal:  Nature       Date:  2011-08-31       Impact factor: 49.962

3.  Interleukin-10 determines viral clearance or persistence in vivo.

Authors:  David G Brooks; Matthew J Trifilo; Kurt H Edelmann; Luc Teyton; Dorian B McGavern; Michael B A Oldstone
Journal:  Nat Med       Date:  2006-10-15       Impact factor: 53.440

4.  Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.

Authors:  H L Kaufman; J B Rao; K R Irvine; V Bronte; S A Rosenberg; N P Restifo; K R Irivine
Journal:  J Immunother       Date:  1999-11       Impact factor: 4.456

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

6.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

Authors:  Sunil R Hingorani; Lifu Wang; Asha S Multani; Chelsea Combs; Therese B Deramaudt; Ralph H Hruban; Anil K Rustgi; Sandy Chang; David A Tuveson
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

7.  Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.

Authors:  Kenji Yokoi; Isaiah J Fidler
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

8.  Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.

Authors:  R M Berman; T Suzuki; H Tahara; P D Robbins; S K Narula; M T Lotze
Journal:  J Immunol       Date:  1996-07-01       Impact factor: 5.422

9.  IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs.

Authors:  Jan Emmerich; John B Mumm; Ivan H Chan; Drake LaFace; Hoa Truong; Terrill McClanahan; Daniel M Gorman; Martin Oft
Journal:  Cancer Res       Date:  2012-05-11       Impact factor: 12.701

10.  Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours.

Authors:  C T Hiley; M Yuan; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2009-11-05       Impact factor: 5.250
  10 in total
  10 in total

1.  Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.

Authors:  Giulia Mesiano; Roberta Zini; Giulia Montagner; Nicoletta Bianchi; Rossella Manfredini; Antonella Chillemi; Massimo Aglietta; Giovanni Grignani; Ilaria Lampronti; Erika Fiorino; Fabio Malavasi; Dario Sangiolo; Roberto Gambari; Davide Ferrari
Journal:  Mol Med       Date:  2017-08-09       Impact factor: 6.354

2.  Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells.

Authors:  Mahboubeh Yazdanifar; Ru Zhou; Pinku Mukherjee
Journal:  Curr Trends Immunol       Date:  2016

Review 3.  An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer.

Authors:  Maryum Nisar; Rehan Zafar Paracha; Sidra Adil; Sumair Naseem Qureshi; Hussnain Ahmed Janjua
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

4.  Inhibitory mechanism of peptides with a repeating hydrophobic and hydrophilic residue pattern on interleukin-10.

Authors:  Guoying Ni; Yuejian Wang; Scott Cummins; Shelley Walton; Kate Mounsey; Xiaosong Liu; Ming Q Wei; Tianfang Wang
Journal:  Hum Vaccin Immunother       Date:  2016-09-29       Impact factor: 3.452

5.  ING4 expressing oncolytic vaccinia virus promotes anti-tumor efficiency and synergizes with gemcitabine in pancreatic cancer.

Authors:  Yinfang Wu; Xiaozhou Mou; Shibing Wang; Xing-E Liu; Xiaodong Sun
Journal:  Oncotarget       Date:  2017-09-20

6.  Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.

Authors:  Zuqiang Liu; Roshni Ravindranathan; Pawel Kalinski; Z Sheng Guo; David L Bartlett
Journal:  Nat Commun       Date:  2017-03-27       Impact factor: 14.919

Review 7.  Immunotherapy for pancreatic cancer.

Authors:  Elias Kotteas; Muhammad Wasif Saif; Konstantinos Syrigos
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-03       Impact factor: 4.322

Review 8.  Prospects for combined use of oncolytic viruses and CAR T-cells.

Authors:  Adam Ajina; John Maher
Journal:  J Immunother Cancer       Date:  2017-11-21       Impact factor: 13.751

9.  Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer.

Authors:  Wanyuan Chen; Weimin Fan; Guoqing Ru; Fang Huang; Xiaming Lu; Xin Zhang; Xiaozhou Mou; Shibing Wang
Journal:  Oncol Rep       Date:  2018-10-24       Impact factor: 3.906

Review 10.  Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.

Authors:  Molly C Holbrook; Dakota W Goad; Valery Z Grdzelishvili
Journal:  Cancers (Basel)       Date:  2021-03-09       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.